TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6159391

Group type: EXPERIMENTAL
Intervention: Somatostatin (0.025 mg/h)
Number of subjects: 6
Study: 30521662

Group type: EXPERIMENTAL
Intervention: Short dental implants
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional dental implants
Number of subjects: 46
Study: 27477476

Group type: EXPERIMENTAL
Intervention: Intervention group (patient‐practitioner communication training)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 184
Study: 25588294

Group type: EXPERIMENTAL
Intervention: Varenicline (active pill plus placebo patch)
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Nicotine patch (active patch plus placebo pill)
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Placebo (placebo pill plus placebo patch)
Number of subjects: 1246
Study: 24175463

Group type: EXPERIMENTAL
Intervention: Vigorous exercise before vocabulary recall and comprehension learning activity
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vigorous exercise after vocabulary recall and comprehension learning activity
Number of subjects: 90

Group type: COMPARATOR
Intervention: Moderate exercise
Number of subjects: 90

Group type: COMPARATOR
Intervention: No physical exercise
Number of subjects: 90
Study: 21430090

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (education and exercise training) for 3 months
Number of subjects: 251

Group type: COMPARATOR
Intervention: High fatigue group
Number of subjects: 251
Study: 19075276

Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (RP) plus beta-carotene (BC)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (RP) alone
Number of subjects: 162

Group type: COMPARATOR
Intervention: Low-dose 13-cis retinoic acid (13cRA)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Grades 2 and higher adverse events
Number of subjects: 162
Study: 17098749

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (varied levels)
Number of subjects: 1691

Group type: EXPERIMENTAL
Intervention: Drinking frequency
Number of subjects: 1691
Study: 15121121

Group type: EXPERIMENTAL
Intervention: Dermagraft and compression therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Compression therapy alone
Number of subjects: 18
Study: 11602028

Group type: EXPERIMENTAL
Intervention: Rivastigmine (3, 6, or 9 mg/d)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rivastigmine responders
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rivastigmine non-responders
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo-treated patients
Number of subjects: 27
Study: 9158266

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 micrograms/g)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Coal tar/2% allantoin/0.5% hydrocortisone cream
Number of subjects: 122
Study: 7701788

Group type: EXPERIMENTAL
Intervention: Group I (patients with hereditary factors)
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Group II (controls)
Number of subjects: 1119
Study: 3284406

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.008 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine (0.333 mg/kg)
Number of subjects: 0
Study: 30016477

Group type: EXPERIMENTAL
Intervention: SPEEK programme (11 interactive lessons)
Number of subjects: 1822

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 1822
Study: 26882111

Group type: EXPERIMENTAL
Intervention: Transitional care bridge program intervention
Number of subjects: 674

Group type: COMPARATOR
Intervention: CGA-only arm
Number of subjects: 674
Study: 25398799

Group type: EXPERIMENTAL
Intervention: Melatonin 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 22154798

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 411

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting
Number of subjects: 411
Study: 20545688

Group type: EXPERIMENTAL
Intervention: Probiotic milk containing Lactobacillus rhamnosus GG, L. acidophilus La‐5, and Bifidobacterium animalis subsp. lactis Bb‐12
Number of subjects: 415

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Probiotic milk
Number of subjects: 415
Study: 18462811

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Patients with major depression
Number of subjects: 28
Study: 15144477

Group type: COMPARATOR
Intervention: Double-blind placebo-controlled food challenges (DBPCFCs) to cow's milk, hen's egg, wheat, and soy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Food-specific IgE and APT
Number of subjects: 64
Study: 12138268

Group type: EXPERIMENTAL
Intervention: Cuprammonium (CU) dialyser
Number of subjects: 8

Group type: COMPARATOR
Intervention: Polysulfon (PS) dialyser
Number of subjects: 8
Study: 11475719

Group type: EXPERIMENTAL
Intervention: Ticlid 250 mg orally, once a day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Panax notoginseng (PNG) 8 ml in 250 ml of normal saline intravenous drip once a day
Number of subjects: 58
Study: 7644096

Group type: EXPERIMENTAL
Intervention: beta‐IFN (3,000,000 UI i.m. on alternate days for 4 weeks)
Number of subjects: 94

Group type: COMPARATOR
Intervention: alpha‐2A‐IFN (3,000,000 UI i.m. on alternate days for 4 weeks)
Number of subjects: 94
Study: 2612535

Group type: EXPERIMENTAL
Intervention: Activated charcoal 4 g/day
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Activated charcoal 8 g/day
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Activated charcoal 16 g/day
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Activated charcoal 32 g/day
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cholestyramine 16 g
Number of subjects: 17

Group type: COMPARATOR
Intervention: Activated charcoal 8 g + cholestyramine 8 g
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Activated charcoal
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cholestyramine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Activated charcoal + cholestyramine
Number of subjects: 17
Study: 122071

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG) added to existing bronchodilators and/or steroid therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (existing bronchodilators and/or steroid therapy without DSCG)
Number of subjects: 0
Study: 30592662

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 319

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 319
Study: 28847455

Group type: EXPERIMENTAL
Intervention: Cannabis Use Reduction (n=152)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Cannabis Use Increase (n=150)
Number of subjects: 302
Study: 26042589

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 5 mg
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 25 mg
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study: 23942558

Group type: EXPERIMENTAL
Intervention: HRC display monitoring
Number of subjects: 2989

Group type: COMPARATOR
Intervention: Nondisplay group
Number of subjects: 2989
Study: 22375409

Group type: EXPERIMENTAL
Intervention: Kangai injection plus FLAG regimen
Number of subjects: 49

Group type: COMPARATOR
Intervention: FLAG regimen
Number of subjects: 49
Study: 19114859

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg twice daily
Number of subjects: 821

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Younger age at enrolment (age 16-19)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Alcohol consumption at enrolment (> or =30 drinks/week)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Paid sex within the previous 3 months
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Recent infection with gonorrhoea
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Injections in the previous 3 months
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Living in the recruitment community for less than 2 years
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Exposure to hormonal contraception
Number of subjects: 821
Study: 16444457

Group type: EXPERIMENTAL
Intervention: Sulodexide
Number of subjects: 150

Group type: COMPARATOR
Intervention: Acenocoumarol
Number of subjects: 150
Study: 14557887

Group type: EXPERIMENTAL
Intervention: Medical treatment for infections, allergies, gastroesophageal reflux, and environmental irritants.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medical voice-hygiene advice including the use of the Accent method.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Retrospective group treated medically.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phonetograms measured in all groups.
Number of subjects: 30
Study: 11434830

Group type: EXPERIMENTAL
Intervention: Abciximab (n=5476)
Number of subjects: 8555

Group type: COMPARATOR
Intervention: Placebo (n=3079)
Number of subjects: 8555

Group type: EXPERIMENTAL
Intervention: Abciximab (n=4680, excluding EPIC bolus-only group)
Number of subjects: 8555

Group type: COMPARATOR
Intervention: Placebo (n=3023, excluding EPIC bolus-only group)
Number of subjects: 8555

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 8555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8555

Group type: EXPERIMENTAL
Intervention: Abciximab with standard-dose heparin
Number of subjects: 8555
Study: 9627510

Group type: EXPERIMENTAL
Intervention: Bile acids (ursodeoxycholic acid 500 mg and chenodeoxycholic acid 500 mg per day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Bile acids (ursodeoxycholic acid and chenodeoxycholic acid)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Bile acids and Placebo
Number of subjects: 102
Study: 7889908

Group type: EXPERIMENTAL
Intervention: Program E (Health Belief Model)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Program EP (Health Belief Model + social psychology of compliance exercises)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 295
Study: 3622581

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29020321

Group type: EXPERIMENTAL
Intervention: SII RMAb
Number of subjects: 200

Group type: COMPARATOR
Intervention: HRIG
Number of subjects: 200
Study: 27788416

Group type: EXPERIMENTAL
Intervention: TPB‐based intervention programme (individual instruction, group education, telephone counselling)
Number of subjects: 285
Study: 24557028

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446

Group type: COMPARATOR
Intervention: Oral prednisone
Number of subjects: 446

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Race/Ethnicity (Black)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Race/Ethnicity (White)
Number of subjects: 446
Study: 24095300

Group type: COMPARATOR
Intervention: Trastuzumab (4 mg/kg load, then 2 mg/kg intravenously weekly until surgery)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Lapatinib (1250 mg orally daily until surgery)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Weekly trastuzumab plus lapatinib (750 mg orally daily until surgery)
Number of subjects: 529
Study: 21419792

Group type: EXPERIMENTAL
Intervention: Intervention (IV) group, n=55
Number of subjects: 121

Group type: COMPARATOR
Intervention: Comparison group (CG), n=20
Number of subjects: 121
Study: 18566882

Group type: EXPERIMENTAL
Intervention: LEGO therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SULP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 16989205

Group type: EXPERIMENTAL
Intervention: SMC electrophoresis of peat mud diluted with distilled water
Number of subjects: 65
Study: 15153818

Group type: COMPARATOR
Intervention: Saline injection (Control group)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of fibrin (Group 2)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fibrin composition with deferoxamine and VEGF(165) (Group 3)
Number of subjects: 23
Study: 10955016

Group type: EXPERIMENTAL
Intervention: CSE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibrates
Number of subjects: 0
Study: 8636309

Group type: EXPERIMENTAL
Intervention: 5 mg finasteride daily for 6-18 days (group 1)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 5 mg finasteride daily for 23-73 days (group 2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 5 mg finasteride daily for 3 months to 4 years (group 3)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 26
Study: 1308375

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg midazolam administered rectally as premedication
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.35 mg/kg midazolam administered rectally as premedication
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg midazolam administered rectally as premedication
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study: 3542771

Group type: EXPERIMENTAL
Intervention: 10 ml Novaluzid 1 and 3 hours after each meal and at bedtime for 2 weeks
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 10 ml Novaluzid 1 and 3 hours after each meal and at bedtime for 4 weeks
Number of subjects: 186
Study: 29533244

Group type: EXPERIMENTAL
Intervention: Thin rigid contact lens (CL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corneal protective agent (CPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 0
Study: 27193613

Group type: EXPERIMENTAL
Intervention: HH intervention including: HH products, training about HH guidelines, two team training sessions, reminders and cues for action (posters/stickers)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: HH intervention
Number of subjects: 795
Study: 24962039

Group type: EXPERIMENTAL
Intervention: Active moxibustion
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sham moxibustion
Number of subjects: 110
Study: 22955728

Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine (30g alcohol/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Alcoholic red wine (30g alcohol/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Gin (30g alcohol/day)
Number of subjects: 67
Study: 20072067

Group type: EXPERIMENTAL
Intervention: Traditional injury prevention program
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pediatric injury prevention program
Number of subjects: 65
Study: 18541610

Group type: EXPERIMENTAL
Intervention: Parenteral dexamethasone (single dose)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 18373136

Group type: EXPERIMENTAL
Intervention: EMR-based intervention with standardized medication review
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: EMR-based intervention
Number of subjects: 620
Study: 15499252

Group type: EXPERIMENTAL
Intervention: Overnight corneal reshaping (OCR) lenses
Number of subjects: 74

Group type: COMPARATOR
Intervention: Soft daily-wear lenses
Number of subjects: 74
Study: 11733883

Group type: EXPERIMENTAL
Intervention: Transcutaneous measurements of blood gases
Number of subjects: 81
Study: 9230162

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Propranolol
Number of subjects: 0
Study: 8423429

Group type: EXPERIMENTAL
Intervention: Chiropractic treatment including side-lying manipulation (n = 17)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Detuned ultrasound, application of a cold pack, and gentle soft tissue massage (n = 19)
Number of subjects: 36
Study: 3616852

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (3 g in a single intramuscular injection)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g im daily for two days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g im daily for five days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Benzathine penicillin (2.4 X 10(6) units in a single im injection)
Number of subjects: 18
Study: 30841745

Group type: EXPERIMENTAL
Intervention: Web-based caregiver support toolkit
Number of subjects: 0
Study: 30641838

Group type: EXPERIMENTAL
Intervention: IMPACT probability of poor outcome at admission
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Initial plasma concentrations of interleukin (IL)‐6
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Initial plasma concentrations of interleukin (IL)‐8
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Initial plasma concentrations of interleukin (IL)‐10
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: MODS following TBI
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: SOFA score
Number of subjects: 166
Study: 28391736

Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis KB290 + β-carotene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25412093

Group type: EXPERIMENTAL
Intervention: Water exchange
Number of subjects: 473

Group type: COMPARATOR
Intervention: CO2 insufflation
Number of subjects: 473
Study: 24079752

Group type: EXPERIMENTAL
Intervention: Adjuvant S‐1 therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 21816543

Group type: EXPERIMENTAL
Intervention: Bupropion in combination with health education counseling
Number of subjects: 540

Group type: COMPARATOR
Intervention: Non-menthol smoking (control group)
Number of subjects: 540
Study: 19967490

Group type: EXPERIMENTAL
Intervention: UFT (2 x 100‐mg capsules) and leucovorin (1 x 25‐mg tablet) taken after a low-fat meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: UFT (2 x 100‐mg capsules) and leucovorin (1 x 25‐mg tablet) taken after fasting
Number of subjects: 12
Study: 16919112

Group type: EXPERIMENTAL
Intervention: CO2 laser (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cold scalpel (group B)
Number of subjects: 40
Study: 15245618

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 5 years
Number of subjects: 194

Group type: COMPARATOR
Intervention: High-dose oral medroxyprogesterone acetate (MPA) 1 g orally for 9 months
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 194

Group type: COMPARATOR
Intervention: MPA
Number of subjects: 194
Study: 11374600

Group type: EXPERIMENTAL
Intervention: Lidocaine inhalation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ropivacaine inhalation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dyclonine inhalation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline inhalation
Number of subjects: 15
Study: 9039247

Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (38.0 (6.4) mg, pH = 9)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vehicle (0.9% NaCl, pH = 9)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Inhaled frusemide
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 14
Study: 8381758

Group type: EXPERIMENTAL
Intervention: Morphine (100 micrograms/kg iv)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naloxone (80 micrograms/kg iv)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg iv)
Number of subjects: 20
Study: 3121021

Group type: EXPERIMENTAL
Intervention: Gram stained conjunctival smear
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chloramphenicol eye ointment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Culture and microimmunofluorescence test
Number of subjects: 90
Study: 31098985

Group type: COMPARATOR
Intervention: no information
Number of subjects: 488

Group type: COMPARATOR
Intervention: neutral information
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: eating disorders emphasis
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: obesity emphasis
Number of subjects: 488
Study: 29565949

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) applied for 8 minutes
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) applied for 2, 4, or 6 minutes
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) applied for 2, 4, 6, or 8 minutes
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no PRF intervention)
Number of subjects: 36
Study: 27545102

Group type: EXPERIMENTAL
Intervention: External stent
Number of subjects: 93

Group type: COMPARATOR
Intervention: Double J stent
Number of subjects: 93
Study: 24831918

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0
Study: 22373886

Group type: EXPERIMENTAL
Intervention: Multidimensional lifestyle intervention (physical activity program, nutrition lessons, media use, sleep)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Multidimensional lifestyle intervention
Number of subjects: 652
Study: 20709444

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Transobturator suburethral tape (TVT-O)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Both techniques (TVT and TVT-O)
Number of subjects: 72
Study: 19157042

Group type: EXPERIMENTAL
Intervention: 5th grade keepin' it REAL (kiR) curriculum
Number of subjects: 1566

Group type: COMPARATOR
Intervention: Control condition (pre-existing substance use prevention programming)
Number of subjects: 1566
Study: 15748783

Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Estradiol/Progesterone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 12221342

Group type: EXPERIMENTAL
Intervention: Patient information leaflet
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual general practitioner management
Number of subjects: 64